Literature DB >> 30853801

Secondary polycythemia in a sarcoma patient: a commentary about cediranib.

A Awan1, T Alcindor1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30853801      PMCID: PMC6380644          DOI: 10.3747/co.26.4385

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  4 in total

1.  VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis.

Authors:  Betty Y Y Tam; Kevin Wei; John S Rudge; Jana Hoffman; Joceyln Holash; Sang-ki Park; Jenny Yuan; Colleen Hefner; Cecile Chartier; Jeng-Shin Lee; Shelly Jiang; Nihar R Nayak; Nihar R Niyak; Frans A Kuypers; Lisa Ma; Uma Sundram; Grace Wu; Joseph A Garcia; Stanley L Schrier; Jacquelyn J Maher; Randall S Johnson; George D Yancopoulos; Richard C Mulligan; Calvin J Kuo
Journal:  Nat Med       Date:  2006-06-25       Impact factor: 53.440

2.  Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma.

Authors:  Lauren C Harshman; Calvin J Kuo; Bryan Y Wong; Nicholas J Vogelzang; Sandy Srinivas
Journal:  Cancer Invest       Date:  2009-10       Impact factor: 2.176

3.  Cediranib for metastatic alveolar soft part sarcoma.

Authors:  Shivaani Kummar; Deborah Allen; Anne Monks; Eric C Polley; Curtis D Hose; S Percy Ivy; Ismail B Turkbey; Scott Lawrence; Robert J Kinders; Peter Choyke; Richard Simon; Seth M Steinberg; James H Doroshow; Lee Helman
Journal:  J Clin Oncol       Date:  2013-04-29       Impact factor: 44.544

4.  Erythropoietin in the general population: reference ranges and clinical, biochemical and genetic correlates.

Authors:  Niels Grote Beverborg; Niek Verweij; Ijsbrand T Klip; Haye H van der Wal; Adriaan A Voors; Dirk J van Veldhuisen; Ron T Gansevoort; Stephan J L Bakker; Pim van der Harst; Peter van der Meer
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.